DosEmi study protocol: a phase IV, multicentre, open-label, crossover study to evaluate non-inferiority of pharmacokinetic-guided reduced dosing compared with conventional dosing of emicizumab in people with haemophilia A.
BMJ open（2023）
摘要
V.4.1 on 28 October 2022 (DosEmi protocol_V4.1; NL81112.041.22).
更多查看译文
关键词
bleeding disorders & coagulopathies, epidemiologic studies, paediatrics, clinical pharmacology, clinical trials
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要